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The auditory brainstem implant (ABI) was first developed nearly 40 years ago and
provides auditory rehabilitation to patients who are deaf and ineligible for cochlear
implant surgery due to abnormalities of the cochlea and cochlear nerve. The aims of
the following review are to describe the history of the ABI and innovations leading up
to the modern ABI system, as well as highlight areas of future development in implant
design.
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INTRODUCTION
The auditory brainstem implant (ABI) is a neuroprosthetic device that provides hearing sensations
to deaf patients who are ineligible for the cochlear implant (CI) due to anatomic constraints. The
ABI bypasses the cochlear nerve to electrically stimulate second order neurons in the cochlear
nucleus (CN) using a multichannel surface array in patients with cochlear and retrocochlear
pathologies.
The first ABI was developed at the House Ear Institute (HEI) in the 1970s (Edgerton et al.,
1982). Similar to a CI, an ABI consists of an external ear-level worn device and an internal
receiver-stimulator implant. The external system consists of a battery source, microphone, speech
processor, transmitter coil, and magnet worn above and behind the ear (Figure 1A); the internal
system consists of a surgically placed receiver-stimulator and magnet (in patients who require
frequent magnetic resonance imaging (MRI), the magnet is removed and replaced with a metallic
non-magnetic spacer at the time of ABI placement), a ground electrode, and an electrode array
(Figures 1B,C). Unlike thin and flexible CI electrodes that follow the curved spatial arrangement of
frequency selectivity in the cochlea (tonotopic axis), ABI electrodes are embedded in flat and rigid
Silastic paddle that lies along the highly curved surface of the CN in the brainstem (Guex et al.,
2015). Advancements have been made in the external speech processor and receiver stimulator
technology but are otherwise identical to systems used for CIs. The basic design of the ABI
multichannel array, however, has not changed in several decades.
Over one thousand ABIs have been placed in deaf adults and children around the world
and is the most commonly placed surface stimulator in the central nervous system. The
ABI was approved by the United States Food and Drug Administration (FDA) in 2000
for patients with Neurofibromatosis type 2 (NF2) and there are no audiologic criteria.
Approximately one in every 25,000 individuals is diagnosed with NF2, and all NF2 patients
will eventually experience profound hearing loss secondary to the tumor growth, radiation
effects, and/or surgical resection of bilateral vestibular schwannomas (VS). This represents the
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FIGURE 1 | Components of the ABI. (A) External system consisting of a
battery, microphone, speech processor, and transmitter coil and magnet,
identical to the modern cochlear implant (CI). (B) Internal system includes a
receiver-stimulator (that is affixed against the skull and above the craniotomy
defect), a multichannel electrode array (that is placed through the lateral
recess of the fourth ventricle), and a ground electrode (that is inserted against
the calvarium and under the temporalis muscle). (C) Close-up of modern
21-electrode array. (D) Side-by-side comparison of three generations of ABI
electrode designs. From left to right: left, platinum ball-style electrode
implanted in the first patient in 1979; middle, two-plate platinum electrode
with Dacron backing created in 1980; right, early multichannel ABI model with
eight electrodes first used in 1992; constructed from platinum and medical
grade silicone. Adapted with permissions from Brackmann et al. (1993).
largest clinical population in the United States that could
potentially benefit from an ABI. Beyond NF2, expanded
indications for ABI implantation have been explored in non-
tumor adults and children and there are, a handful of
clinical studies in the United States and abroad. Together
these indications include bilateral cochlea and cochlear nerve
aplasia and hypoplasia, traumatic nerve avulsion, and cochlear
ossification accounting for an additional 2.1% of all individuals
with profound sensorineural hearing loss who meet indications
for an ABI (Kaplan et al., 2015).
The aims of the following review article are to (1) describe
the history of the ABI and innovations leading up to the modern
ABI system, and (2) review clinical outcomes with the ABI and
highlight areas of future development in implant design and
performance.
ELECTRICALLY EVOKED AUDITORY
SENSATIONS AND THE COCHLEAR
IMPLANT
Concepts in electrically evoked hearing date back to the early
1800s, when Alessandro Volta, inventor of the modern battery,
applied electrical current through metal probes to his ear
canals, evoking sounds described as “crackling” or “bubbling”
(Volta, 1982). A few decades later, French neurologist Guillaume
Duchenne tested electrically evoked auditory sensations by using
an alternating electrical current to stimulate the cochlea that was
associated with a “buzzing” and “ringing” sound (Duchenne and
Poore, 1883).
One of the earliest studies to elicit auditory sensations was
performed in 1957, when Djourno and Eyries restored hearing
sensations in a deaf patient by directly stimulating the cochlear
nerve (Djuorno and Eyries, 1957). Electrodes were placed on the
cochlear nerve and sound sensations were successfully generated
when a current was passed through the electrodes. The patient
was able to discriminate sound intensity and recognize limited
closed-set speech. Inspired by this early work, Dr. William F.
House and Dr. John Doyle implanted deaf patients with an early
CI prototype that consisted of a single ball electrode. Outcomes
from these initial CIs were encouraging, with patients obtaining
both frequency discrimination and closed set speech recognition.
Together, these early observations underscored the feasibility of
electrically evoked auditory percepts and laid the foundation for
the development of early ABI devices.
INITIAL APPLICATIONS IN
NEUROFIBROMATOSIS TYPE 2
Neurofibromatosis type 2 or NF2 is a devastating autosomal
dominant genetic syndrome characterized by mutations of
the NF2 tumor suppressor gene leading to an increased
risk for central nervous system tumors including bilateral
VS, meningiomas and ependymomas (Evans, 2009). VS are
benign tumors that arise from the vestibular component of the
vestibulocochlear nerve. VS are associated with hearing loss
through these mechanisms: (1) tumor growth in the internal
auditory canal and cerebellopontine angle, (2) iatrogenic injury
during tumor resection (Sughrue et al., 2011) or (3) following
radiation therapy.
Patients with NF2 often develop postlingual profound hearing
loss as their disease progresses. Tinnitus, disequilibrium, and
lower cranial nerve involvement (dysarthria, dysphagia, and
hoarseness) are also common (Matthies and Samii, 1997). Due to
retrocochlear hearing loss, deaf NF2 patients with cochlear nerve
damage are not candidates for traditional CIs except in unusual
circumstances (Peng et al., 2018). Thus, since the ABI bypasses
the auditory periphery and stimulates the CN, NF2 patients were
identified as an ideal population that could benefit from this
device.
In 1979, Drs. William House and William Hitselberger
performed the first ABI implantation on a 51-year-old woman
with NF2 (Hitselberger et al., 1984). During surgery to remove the
VS, a depth electrode was concurrently placed into the substance
of the CN. This early ABI model was designed with a ball-style
electrode connected to an external Bosch hearing aid processor
(Figure 1D). These bipolar electrodes were connected to a single
channel system, and together provided electrical stimulation
across the CN. The patient recovered from surgery and received
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meaningful auditory sensations, including environmental sound
awareness and improved lipreading (Eisenberg et al., 1987).
In 1980, researchers at the Huntington Medical Research
Institute (Pasadena, CA, United States) developed an updated
ABI device using a House/3M CI processor and two-plate
electrode design made from polyethylene terephthalate mesh,
which improved the handling and positional stable in animal
models (Bullara et al., 1979; Figure 1D). Two years after initial
implantation, the first patient underwent revision surgery due
to lower extremity side effects and loss of auditory sensation
attributed to a shift in the ball-style electrodes from their original
position. For the revision, the patient was implanted with a new
ABI device. The patient recovered well from revision surgery,
benefited from the ABI, and no longer experienced any further
shift in array position (Eisenberg et al., 1987). This patient
continues daily use of the ABI device three decades later (Colletti
et al., 2012).
Single-Channel ABI System
From 1979 to 1991, 25 NF2 patients at HEI were implanted
with a single-channel ABI system with dual-ball electrodes in
the first patient, a two-plate electrode design in the next 19
patients, and a three-plate electrode design in the last five patients
(Brackmann et al., 1993). Among this initial ABI cohort, three
patients required revision surgery for device failure. Some users
also experienced various minor technical and medical difficulties.
Two patients experienced broken wires; four patients experienced
percutaneous electrical plug connector infections; two patients
developed postoperative meningitis treated with antibiotics; nine
patients developed cerebrospinal fluid leaks treated with mastoid
pressure dressings, surgical exploration and repacking, or lumbar
drainage (Brackmann et al., 1993). Audiometric outcomes were
promising, with the majority of patients receiving environmental
sound awareness and obtaining subjective auditory benefit from
their ABIs.
Multi-Channel ABI System
These early patient experiences, along with parallel developments
in CIs, prompted the development of a multichannel ABI
by Laszig et al. (1991) in collaboration with Cochlear Ltd.
(Sydney, Australia). With a multichannel system, different
frequencies could be coded based on changes in the pattern of
electrode activation, increasing programming flexibility. Among
other design updates, the new device also included a mesh-
style electrode array with three platinum plates mounted on
polyethylene terephthalate mesh. Two versions of this device
were produced (Laszig et al., 1999): a European model with 21
electrodes (Nucleus 22) and a North American model with eight
electrodes (Otto et al., 2002; Figure 1D).
Starting in 1992, the Nucleus multichannel ABI device
(Cochlear Corp., Englewood, CO, United States) replaced older
ABI models in North America and abroad. Between September
1992 and October 1996, 27 NF2 patients with bilateral VS
underwent ABI surgeries at the University of Verona, in
Verona, Italy representing the first cohort to receive the new
multichannel ABI device (Nevison et al., 2002). There were
no major surgical complications and audiometric outcomes
were better than single channel systems, with most ABI
users achieving environmental sound awareness and improved
pattern recognition for lipreading; two users were capable
of understanding everyday conversation without lipreading,
an achievement not seen with the earlier single channel
systems.
In North America, multichannel ABIs were first implanted
by surgeons at HEI (Schwartz et al., 2003). Starting in 1992,
a total of 71 NF2 patients were implanted with the 8-
electrode (North American) multichannel ABI. There were
no major surgical complications; two patients developed CSF
leaks treated with pressure dressings and lumbar drainage.
Consistent with European outcomes, most ABI users achieved
environmental sound awareness and the majority scored above
chance on closed-set word recognition. Together, outcomes in
the United States and in Europe demonstrated the safety and
efficacy of multichannel ABI systems. These studies paved the
way for FDA approval in 2000 of the Nucleus 24 ABI and ABI 541
(2016) for use in NF2 individuals ages 12 and older (Otto et al.,
2002). The launch of the newest ABI (ABI541) was announced
in February 2016, which improved upon older models with a
newer receiver/stimulator and removable magnet, supporting
MRI usage.
Recent outcomes have shown that the majority of NF2 patients
implanted with the ABI achieve some phoneme discrimination
and environmental sound awareness, however, only a minority
obtain open set speech discrimination (Ramsden et al., 2016).
Indeed, ABI outcomes overall remain inferior compared to
the traditional CI. Only a few ABI users achieve open-set
speech, and the majority rely on lip-reading and sign language
for their communication needs. Most ABI users report only
environmental sound awareness. Brainstem trauma has been
identified as a major factor in the variability of ABI outcomes in
NF2 patients, and surgical position, length of deafness, number
of pitch electrodes, perceptual levels, and ABI stimulation rate all
correlate to speech recognition in these patients.
An early improvement to ABI surgery was the use of
intraoperative monitoring to guide placement of the ABI
electrode array (Waring, 1995). Monitoring is essential because
the array is placed in a “blind” fashion without direct visual
cues to the position of the CN. Intraoperative monitoring relies
on far field electrically evoked auditory brainstem responses
(EABRs) that are obtained by delivering single, biphasic pulses
to the ABI array through a processor and coil, and responses
are recorded using a vertex (+) to nape (–) schema with the
ground electrode at the hairline. Responses to stimulation of
electrode pairs in the electrode array help determine the ideal
paddle position most likely to elicit auditory precepts from the
CN. Intraoperative EABRs are used to adjust array position and
ensure the array has not shifted during surgical closure of the
dura and soft tissue (Puram et al., 2015). However, even with
EABR monitoring, the resulting positions of the electrode arrays
are highly variable from patient to patient (Barber et al., 2017).
This was shown by three-dimensional multiplanar reconstruction
of adult and pediatric subjects. This novel study that classified
the precise position of ABI electrode array in children and
adult users demonstrated that this position varied widely among
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ABI users, with some orientations associated with improved
perception and others associated with increased side effects
(Barber et al., 2017). These observations lay the foundation for
future efforts to use intraoperative navigation to help improve
ABI placement.
Penetrating Electrode Auditory
Brainstem Implant
Another strategy to improve the ABI was the development
of the penetrating electrode ABI, or PABI. The PABI is
a hybrid consisting of microelectrodes and standard surface
electrodes. Microelectrodes are designed with varying lengths
to take advantage of the tonotopic organization of the CN
and penetrate deep (1–2 mm) to stimulate neural pathways
inaccessible at the surface. Development began in the early
1990s at HEI in collaboration with Huntington Medical Research
Institutes (Pasadena, CA, United States) and Cochlear Ltd.
(Sydney, Australia) and the final product consisted of 8 or 10
penetrating microelectrodes with 10 or 12 surface electrodes,
respectively. The PABI was solely used as an experimental device
in a clinical trial. In the trial of 10 NF2 patients, the PABI
provided lower thresholds and greater selectivity of electrical
stimulation (Shannon, 2012). However, clinical outcomes were
variable and there was no significant difference in speech
understanding between patients with PABIs and multichannel
ABIs. Additionally, less than 25% of penetrating electrodes
resulted in auditory sensations compared to 60% of surface
electrodes (Otto et al., 2008). The PABI was discontinued because
of serious side effects.
Audiological Considerations
ABIs are programmed using a combination of monopolar and
bipolar stimulation (Herrmann et al., 2015). With monopolar
stimulation, psychophysical thresholds for each individual
electrode in the array are measured in an ascending method
starting at current levels below perception. Once auditory
sensations are evoked, loudness comfort limits are determined
by raising the current level from threshold to the level at
which the subject first experiences uncomfortable loudness or
side effects such as tactile stimulation, dysgeusia, or dizziness.
For bipolar stimulation, electrical stimuli are delivered using
biphasic single pulses that alternate in polarity. The phase
of biphasic pulses alternates temporally between anodic and
cathodic (13 pps, 150 µs phase duration, 8 µs interphase
gap) to provide optimal cancellation of stimulus artifact during
electrophysiologic testing. Specific bipolar electrode pairs are
selected with a goal of sampling a variety of areas on the
electrode pad. Similar to monopolar stimulation, psychophysical
thresholds are measured for each bipolar electrode pair using
an ascending, bracketing method starting at current levels
below perception. The loudness comfort limits are measured
for each electrode pair by raising the current level from
threshold until the subject first reports uncomfortable loudness
or side effects. Results from monopolar and bipolar perceptual
testing are used to map electrodes and electrode pairs based
on sensations elicited, and are integral to improving hearing
outcomes with the ABI. Programming techniques vary across
ABI centers due to local differences in training/expertise,
equipment availability, and patient demographics (ex: children
vs. adults).
Cochlear Implantation in NF2 Patients
ABIs represent a major success in restoring a sense of hearing
to NF2 patients with bilateral deafness. However, because ABI
outcomes remain inferior compared to the traditional CI, in
recent years, cochlear implantation has also been revisited as a
treatment option in patients who have preserved continuity of
the cochlear nerve. Kveton et al. (1989) reported the first staged
CI in a patient who previously underwent VS resection using
the translabyrinthine approach. Postimplantation performance
was comparable to performance in non-tumor post-lingual
implant recipients, which underscored the viability of auditory
stimulation in this patient population. A few years later in 1995,
the first simultaneous cochlear implantation with VS removal was
performed by Arriaga et al. with results supported by similar
early reports (Arriaga and Marks, 1995; Ahsan et al., 2003).
Normal function of the CI and improved hearing postoperatively
in these patients suggested that enough cochlear nerve fibers
were preserved to allow for adequate stimulation by a CI, despite
tumor pressure and surgical dissection. Since these case reports,
several series have corroborated favorable audiometric outcomes
in select NF2 patients who receive CIs (Lloyd et al., 2014), with
some studies demonstrating up to 70–85% of patients achieving
open-set speech discrimination (Carlson et al., 2012; Lassaletta
et al., 2016). In a literature review of 108 patients with cochlear
nerve deficiency, 25% achieved open set speech perception, 34%
attained closed-set speech perception, and 41% achieved sound
detection, suggesting that CI instead of ABI may be a beneficial in
select NF2, with the potential of lower morbidity (Vesseur et al.,
2018).
Successful hearing rehabilitation in NF2 patients using CI
depends on careful preoperative assessment to confirm a viable
cochlear nerve. Several tests exist to evaluate the functionality
of the cochlear nerve. These include evoked compound action
potentials (eCAPs) to determine the responsiveness of the
cochlear nerve to cochlear stimulation and cochlear nerve
action potentials (CNAPs), which may have greater predictive
power when combined with fast ABRs.(Piccirillo et al., 2008).
Intraoperatively, ABRs and EABRs can also be used for cochlear
nerve monitoring as previously described. Postoperatively,
promontory stimulation can be used to test the integrity of the
cochlear nerve after VS resection. A review of these various tools
to test the functionality of the cochlear nerve are reviewed by
Lassaletta et al. (2017).
OUTCOMES OF THE ABI IN
NON-TUMOR PATIENTS
Colletti et al. (2005) postulated that patients who were deaf
from non-tumor cochlear or cochlear nerve pathologies could
also benefit from ABIs. Both congenital and acquired conditions
can disrupt the normal structure or function of the cochlea
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and cochlear nerve. Examples include congenital cochlear nerve
aplasia, temporal bone fractures that involve the cochlea or
internal auditory canal, labyrinthitis ossificans from bacterial
meningitis, and extensive cochlear otosclerosis (Sennaroglu et al.,
2011; Merkus et al., 2014).
Interestingly, early clinical outcomes data in these patients
suggest that non-tumor ABI users may benefit more than
NF2 patients. For example, while only a small minority of
NF2 patients are capable of open-set sentence recognition, a
significant number of non-tumor patients achieve open set
speech perception (Colletti and Shannon, 2005). In four patients
with cochlear ossification, three achieved open-set sentence
recognition and could engage in normal conversation, and in
six patients with head trauma (four with bilateral labyrinthine
fractures and two with bilateral temporal bone fractures) all
achieved closed-set word recognition, with three achieving open-
set speech recognition and two even able to engage in everyday
oral conversation (Colletti et al., 2005).
ABI in Children
Kaplan et al. (2015) estimated that 2.1% of all deaf children
in the United States have bilateral cochlea or cochlear nerve
aplasias, making them ideal candidates for ABI surgery.
Providing early sound perception is important in children
due to cortical plasticity and critical development of central
auditory processing (Kaplan et al., 2016). The first three non-
tumor individuals implanted with the ABI were prelingually deaf
children born with bilateral cochlear malformations and cochlear
nerve aplasia (Colletti et al., 2002). After surgery, all children
achieved environmental sound awareness, one achieved speech
recognition, and another achieved moderate speech detection.
The first ABI patient with auditory neuropathy was also a child
(Colletti et al., 2004). This patient was a 6-year-old with severe
congenital sensorineural hearing loss. As early as 2 months
after activation, the child demonstrated environmental sound
awareness and word detection.
Over the past few years, indications have continued to expand.
In a recent study of patients with inner ear malformations,
Sennarog˘lu et al. (2016) found that among 60 children (12–
64 months) with severe inner ear malformations, 46.7% achieving
closed set discrimination and 20% developing open set speech
discrimination after receiving the ABI. In the United States,
there are three active FDA trials (Massachusetts Eye and Ear,
New York University, and Children’s Hospital Los Angeles)
recruiting pediatric candidates for the ABI. In the most recent
update of the clinical trial in Boston, both primary and
revision ABI surgery in children were performed successfully
without any major or minor complications (Puram et al.,
2016). All children achieved environmental sound awareness,
and several demonstrated babbling and mimicry. This was the
first study in the United States to report outcomes following
pediatric ABI surgery, and results were consistent with studies
performed abroad (Sennaroglu et al., 2009; Colletti et al.,
2010).
Today, over 100 non-tumor pediatric patients have been
implanted with ABIs in centers across the world (Noij
et al., 2015). Surgical and audiometric outcomes vary but
most pediatric ABIs overall experience meaningful auditory
sensation and improved communication abilities. In some cases,
pediatric ABI users with no neurodevelopmental concerns can
achieve open set speech understanding (Sennarog˘lu et al.,
2016). Nevertheless, pediatric ABI users generally have inferior
audiometric outcomes compared to CI users (Puram et al.,
2016).
FUTURE DIRECTIONS
Despite advancements in ABI technology over the past few
decades, several challenges remain. A key limitation of current
ABIs is the highly variable and often unpredictable audiometric
outcomes; indeed, while some patients achieve open-set speech
perception, the majority experience limited environmental sound
awareness and speech pattern recognition (Colletti et al., 2005,
2009; Noij et al., 2015). The reasons for the variability in
outcomes are not known. One explanation in tumor patients is
that the tumor, or surgery to remove it, has damaged CN neurons
that are important in coding for speech (Colletti and Shannon,
2005). Also, as mentioned earlier, positions of the ABI array
vary from patient to patient (Barber et al., 2017). Finally, there
are limitations of electrical stimulation, which is susceptible to
channel cross talk, activation of competing pathways, and non-
auditory side effects. These shortcomings may be even more
pronounced with brainstem implants due to the unpredictable
neural pathways in the CN compared to the highly tonotopic
spiral ganglion that is stimulated by the CI.
Optogenetics
A novel strategy to improve brainstem implants is through
the use of light to control genetically modified cells, a field
known as optogenetics (Deisseroth et al., 2006). Compared
to electricity, light has the advantage of increased specificity,
which allows for selective stimulation and inhibition of neural
pathways. To sensitize human tissue to visible light, a viral
vector-mediated delivery of light-sensitive channel proteins is
currently applied. One of the first studies to demonstrate the
feasibility of optogenetically controlled auditory stimulation
was performed by Darrow et al. (2015) who used adeno-
associated viral gene transfers to express channelrhodopsin-2
(ChR2) in a murine model (Darrow et al., 2015; Kozin et al.,
2015). Using an optical fiber coupled to a blue light laser
directed at the infected dorsal CN, excitatory spiking activity
was achieved in the inferior colliculus and auditory cortex
(Figure 2).
In 2014, a new channelrhodopsin called Chronos was
isolated by Klapoetke et al. (2014) from the algal species
Stigeoclonium helveticum. Testing showed that Chronos had high
light sensitivity and faster channel kinetics than any previous
channelrhodopsin, making it ideal for optogenetically based
auditory implants. Since its discovery, Chronos has continued
to show promise in both in vivo and behavioral studies, and is
capable of a wide range of temporal stimulation rates for better
discriminability in auditory neural circuits (Shimano et al., 2013;
Guo et al., 2015). In one experiment, light-evoked responses
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FIGURE 2 | Surgical view of an optogenetic experiment that stimulates the
photosensitized left dorsal CN (green arrow) using pulsed radiant energy in a
mouse model. Optical stimulation is delivered by a flexible optical fiber (blue
arrow) coupled to a blue light laser. Direct visualization of the dorsal CN was
achieved using a posterior craniotomy as described by Kozin et al. (2015).
of the older ChR2 opsin were compared with Chronos in a
murine ABI model (Hight et al., 2015). Results showed that
Chronos activated the inferior colliculus at higher stimulation
rates than ChR2. As further research develops, opsin technology
may support the evolution of future optogenetic-based brainstem
implants.
Conformable Electrode Arrays
Modern electrode array designs are flat and result in suboptimal
contact to the complex curvature of the CN and may explain
the poor spectral resolution of most ABI users. Application
of flexible polymers that conform to the brainstem surface
has been an exciting area of research by our group (Minev
et al., 2015; Figure 3). Among conducting polymers, poly(3,4-
ethylenedioxythiophene) (PEDOT) has gained particular interest
for its electrochemical stability, efficient charge transfer, and
biocompatibility (Ludwig et al., 2006; Cui and Zhou, 2007).
In a recent study, the electrode sites of conformable ABI
electrode arrays were coated with PEDOT and polystyrene
sulfonate (PSS); the conformable array allowed for greater access
to the tonotopic axis of the CN in mice and the conductive
polymer (PEDOT:PSS) provided ideal electrical (impedance,
charge injection capacity) and physical characteristics (size,
thickness, bendability) for CN stimulation (Guex et al., 2015).
Studies are soon underway to characterize acute and chronic
responses using conformable arrays in rodent and primate
models.
Electrode Array Position
Regardless of the type of stimulation employed, we must improve
and standardize the placement of the stimulating array. The
promising approach of combined CT and MRI imaging, which
has been used in the auditory midbrain implant (Lim et al.,
2007), may lead to a better understanding of electrode positioning
and more consistent and favorable hearing outcomes in future
FIGURE 3 | Multichannel flexible ABI arrays have been engineered and
fabricated for testing in a collaboration between Massachusetts Eye and Ear
and École Polytechnique Fédérale de Lausanne (EPFL). This photograph
shows a conformable EPFL electrode array developed on thin polyimide
substrate in an experimental rodent model (Guex et al., 2015). Unlike modern
ABI technology, our designs will improve the electrode-tissue interface by
conforming to the convexity of the CN. Adapted with permissions from
Guex et al. (2015).
ABI users. The combination is needed because CT has excellent
resolution of the electrode array and bony structures (Barber
et al., 2017) whereas MRI resolves the neural structures of the
brainstem. This direction is needed to show which positions
have a greater likelihood of CN activation and the best speech
comprehension.
CONCLUSION
Over the past four decades, the ABI has gone through numerous
iterations in device and electrode design. While the ABI was
originally designed for NF2 patients, recent studies suggest a
possible role of this technology to provide hearing in non-tumor
children and adults. While the ABI can restore meaningful sound
awareness in most patients, outcomes remain modest compared
to the average CI user. Improvements in electrode positioning
and development of ABI surgical navigation methods, the
development of new-generation conformable surface arrays, and
optogenetic modulation of the CN neurons are active areas of
research that may improve performance.
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